American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

FDA Seeks Docs' Help in Cracking Down on Misleading Drug Promotions

New Program Will Teach Physicians How to Spot, Report Violations

By News Staff

The FDA announced this week that it is launching a program designed to educate health care professionals so that physicians and others can help the agency prevent the misleading or inaccurate promotion of prescription medications.
FDA News
The Division of Drug Marketing, Advertising, and Communications, or DDMAC, in the agency's Center for Drug Evaluation and Research intends to increase the effectiveness of its surveillance program, especially with regard to inappropriate activity by pharmaceutical sales representatives in physicians' offices and during presentations to health care professionals.

Thus, the agency's new Bad Ad Program aims to ensure that promotional information
  • is accurate,
  • balances the risks and benefits of a product,
  • is consistent with prescribing information approved by the FDA, and
  • includes only information that is supported by strong evidence from clinical studies.
The DDMAC plans to distribute educational materials through partnerships with professional medical organizations. Outreach efforts also will include exhibiting at medical conventions beginning this month.

"The Bad Ad Program will help health care providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency," said Thomas Abrams, R.Ph., M.B.A., director of the DDMAC, in a May 11 news release.

FDA Commissioner Margaret Hamburg, M.D., said in a letter to health care professionals (2-page PDF; About PDFs) that the pharmaceutical industry spends nearly three times as much on advertising to health care professionals as it does on consumer-targeted advertising. Advertising aimed at health care professionals -- which occurs in places such as medical offices, hospitals, pharmacies and medical meetings -- often is beyond the scope of the DDMAC's surveillance efforts.

The DDMAC's monitoring of prescription drug promotion relies on review of industry materials submitted to the FDA, complaints filed by the pharmaceutical industry and field surveillance at large medical conventions, Hamburg said.

"While these efforts are effective, FDA's ability to monitor other promotional activities, which may occur in any number of settings, is limited," Hamburg said in her letter. "With the launch of the Bad Ad Program, FDA seeks to collaborate with health care professionals to address misleading promotion, wherever it may occur."

The FDA said examples of common violations include
  • omitting or downplaying the risks associated with a product;
  • overstating a product's effectiveness;
  • promoting off-label, or unapproved, uses of products; and
  • making misleading drug comparisons.
Physicians are encouraged to report potential violations related to drug promotion by e-mail or by calling (877) RX-DDMAC [79-33622]. Reports may be submitted anonymously, but the FDA encourages physicians to include contact information so that DDMAC officials can follow up, if necessary.

The FDA also has a campaign designed to educate consumers about misleading promotions.

Share this on AAFP Connection

Health of the Public

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing